

Supplementary Table 2. Baseline characteristics of propensity score matched inflammatory bowel disease patients

Characteristics	Total (n = 127)	UC (n = 68)	CD (n = 59)
Age (matching factor)	43.9 ± 15.0	45.8 ± 14.4	41.7 ± 15.5
Female (matching factor)	51 (40.2)	30 (44.1)	21 (35.6)
BMI (kg/m ²)	25.3 ± 16.3	24.3 ± 3.0	26.4 ± 23.7
C-reactive protein (mg/dL)	0.1 (0–5.0)	0.1 (0–2.8)	0.1 (0–5.0)
Albumin (mg/dL)	4.5 (3.4–5.3)	4.4 (3.4–5.3)	4.5 (3.4–5.3)
Haemoglobin (mg/dL)	13.7 (8.8–17.3)	14.0 (10.4–17.1)	13.1 (8.8–17.3)
Hematocrit (mg/dL)	41.5 (27.3–52.0)	42.0 (31.2–51.7)	40.3 (27.3–52.0)
Faecal calprotectin (mg/kg)	112 (0–8,541)	89 (0–8,541)	142 (0–5,683)
Medication			
5-ASA	97 (76.4)	60 (88.2)	37 (62.7)
Azathioprine	66 (52.0)	21 (30.9)	45 (76.3)
Steroid	25 (19.7)	10 (14.7)	15 (25.4)
Biologics	43 (33.9)	19 (27.9)	24 (40.7)
Small molecules	1 (0.8)	1 (1.5)	0
Probiotics	37 (29.1)	22 (32.4)	15 (25.4)
Calcium supplement	9 (7.1)	4 (5.9)	5 (8.5)
Iron supplement	8 (6.3)	1 (1.5)	7 (11.9)
UC phenotype (Montreal classification)			
A1/A2/A3		2 (2.9)/30 (44.1)/36 (52.9)	
E1/E2/E3		38 (55.9)/15 (22.1)/15 (22.1)	
Partial mayo score		3 (0–4)	
Mayo endoscopic sub-score		1 (0–3)	
UCEIS score		2 (0–8)	
CD phenotype (Montreal classification)			
A1/A2/A3			1 (1.7)/35 (59.3)/23 (39.0)
L1/L2/L3			30 (50.8)/3 (5.1)/26 (44.1)
L4+			0
B1/B2/B3			36 (61.0)/16 (27.1)/7 (11.9)
P			6 (10.2)
CDAI			168 (31–365)

Data was expressed as mean ± standard deviation, median (range) or number (%).

BMI, body mass index; ASA, aminosalicylic acid; UC, ulcerative colitis; UCEIS, ulcerative colitis endoscopic index score; CD, Crohn's disease; CDAI, Crohn's disease activity index.